Reliability of Laboratory-Developed Tests Called Into Question
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Pancreatic Cancer
PANCREATIC CANCER ADVISOR
FEATURED CONTENT
-
-
How the Coronavirus Pandemic May Affect Cancer Clinical Trials
Risks of moving clinical trials online include missing key information about the patient experience — and higher dropout rates could also impair the overall quality of trials. -
How Patients Lose Their Own Voices: Disparities in Patient-Reported Outcome Capture in Clinical Trials
It remains important to interrogate how structural discrimination influences the collection of patient-reported outcomes. -
Why Cancer Centers May Need to Rethink the Hard Sell to Patients
Two recent papers are encouraging cancer center executives to rethink how they position their services to potential patients. -
Has the Time for At-Home Cancer Care Finally Come?
A Penn Medicine team debuts its program focused on cancer care at home — just in time for COVID-19.
PANCREATIC CANCER NEWS
Durvalumab-Tremelimumab Plus Chemotherapy Failed to Improve Survival in Pancreatic Cancer Subtype
Potential Markers for High Risk of Pancreatic Cancer Identified
Zenocutuzumab Gets Orphan Drug Designation for Pancreatic Cancer
NALIRIFOX Shows Promising Anticancer Activity in Metastatic Pancreatic Ductal Adenocarcinoma
Neoadjuvant Treatment of Borderline-Resectable Pancreatic Cancer Led to Improved Overall Survival
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Pancreatic Cancer
